Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nanomedicine across Barriers
share announcement

Nanomedicine across Barriers

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 June 2022) | Viewed by 8821

Special Issue Editors

Prof. Barbara Ruozi

E-Mail Website
Guest Editor
Department of Life Science, Universita degli Studi di Modena e Reggio Emilia, Modena, Italy
Interests: nanomedicine; brain delivery; targeting; liposomes; gene therapy; neurodegenerative diseases; cancer
Dr. Jason Thomas Duskey

E-Mail Website
Guest Editor
NanotechLab., Te.Far.T.I. Lab., Unviersity of Modena and Reggio Emilia, Modena, Italy
Interests: brain delivery; GBM; nanoparticles; gene therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanomedicine delivery systems are a hot topic across every field of disease treatment. Of these, lipidic and polymeric nanoparticles have become one of the leading fields. They have been modified and improved to increase stability, drug loading and compatibility, and bioavailability through improved synthesis or conjugation with other molecules; however, the major problem remains of how to further improve the delivery these particles efficiently to the diseased site. Novel methods of surpassing the bodies’ major barriers are needed to improve efficacy, lower toxicity, and off-target effects and create clinically applicable nanomedicine treatments to cure diseases. In this Issue, we want to highlight recent nanomedical carrier advances for the ability to overcome the bodies’ natural barriers for improved treatment. Advances in lipidic and polymeric nanoparticles to overcome the following barriers are of the highest interest: blood–brain barrier, nasal delivery, ocular delivery, topical delivery across the skin, and pulmonary delivery.

Prof. Barbara Ruozi
Dr. Jason Thomas Duskey
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Nanomedicine
  • Overcoming physical delivery barriers
  • Polymeric nanoparticles
  • Lipidic nanoparticles
  • Blood–brain barrier
  • Ocular deliver
  • Intranasal delivery
  • Pulmonary delivery
  • Topical delivery

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 2093 KiB  
Article
Prevention of Postprandial Hyperglycemia by Ophthalmic Nanoparticles Based on Protamine Zinc Insulin in the Rabbit
by Saori Deguchi, Fumihiko Ogata, Takumi Isaka, Hiroko Otake, Yosuke Nakazawa, Naohito Kawasaki and Noriaki Nagai
Pharmaceutics 2021, 13(3), 375; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13030375 - 12 Mar 2021
Cited by 1 | Viewed by 1719
Abstract
Postprandial hyperglycemia, a so-called blood glucose spike, is associated with enhanced risks of diabetes mellitus (DM) and its complications. In this study, we attempted to design nanoparticles (NPs) of protamine zinc insulin (PZI) by the bead mill method, and prepare ophthalmic formulations based [...] Read more.
Postprandial hyperglycemia, a so-called blood glucose spike, is associated with enhanced risks of diabetes mellitus (DM) and its complications. In this study, we attempted to design nanoparticles (NPs) of protamine zinc insulin (PZI) by the bead mill method, and prepare ophthalmic formulations based on the PZI-NPs with (nPZI/P) or without polyacrylic acid (nPZI). In addition, we investigated whether the instillation of the newly developed nPZI and nPZI/P can prevent postprandial hyperglycemia in a rabbit model involving the oral glucose tolerance test (OGTT). The particle size of PZI was decreased by the bead mill to a range for both nPZI and nPZI/P of 80–550 nm with no observable aggregation for 6 d. Neither nPZI nor nPZI/P caused any noticeable corneal toxicity. The plasma INS levels in rabbits instilled with nPZI were significantly higher than in rabbits instilled with INS suspensions (commercially available formulations, CA-INS), and the plasma INS levels were further enhanced with the amount of polyacrylic acid in the nPZI/P. In addition, the rapid rise in plasma glucose levels in OGTT-treated rabbits was prevented by a single instillation of nPZI/P, which was significantly more effective at attenuating postprandial hyperglycemia (blood glucose spike) in comparison with nPZI. In conclusion, we designed nPZI/P, and show that a single instillation before OGTT attenuates the rapid enhancement of plasma glucose levels. These findings suggest a better management strategy for the postprandial blood glucose spike, which is an important target of DM therapy. Full article
(This article belongs to the Special Issue Nanomedicine across Barriers)
►▼ Show Figures

Graphical abstract

15 pages, 3140 KiB  
Article
Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles
by Elisa Rojas-Prats, Carlota Tosat-Bitrián, Loreto Martínez-González, Vanesa Nozal, Daniel I. Pérez and Ana Martínez
Pharmaceutics 2021, 13(2), 180; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13020180 - 28 Jan 2021
Cited by 10 | Viewed by 2580
Abstract
A potent cell division cycle 7 (CDC7) kinase inhibitor, known as PHA-767491, has been described to reduce the transactive response DNA binding protein of 43 KDa (TDP-43) phosphorylation in vitro and in vivo, which is one of the main proteins found to aggregate [...] Read more.
A potent cell division cycle 7 (CDC7) kinase inhibitor, known as PHA-767491, has been described to reduce the transactive response DNA binding protein of 43 KDa (TDP-43) phosphorylation in vitro and in vivo, which is one of the main proteins found to aggregate and accumulate in the cytoplasm of motoneurons in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients. However, the main drawback of this compound is its low permeability to the central nervous system (CNS), limiting its use for the treatment of neurological conditions. In this context, the use of drug delivery systems like nanocarriers has become an interesting approach to improve drug release to the CNS. In this study, we prepared and characterized biodegradable nanoparticles in order to encapsulate PHA-767491 and improve its permeability to the CNS. Our results demonstrate that poly (lactic-co-glycolic acid) (PLGA) nanoparticles with an average radius between 145 and 155 nm could be used to entrap PHA-767491 and enhance the permeability of this compound through the blood–brain barrier (BBB), becoming a promising candidate for the treatment of TDP-43 proteinopathies such as ALS. Full article
(This article belongs to the Special Issue Nanomedicine across Barriers)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

30 pages, 433 KiB  
Review
The Use of Micro- and Nanocarriers for Resveratrol Delivery into and across the Skin in Different Skin Diseases—A Literature Review
by Beata Szulc-Musioł and Beata Sarecka-Hujar
Pharmaceutics 2021, 13(4), 451; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13040451 - 26 Mar 2021
Cited by 21 | Viewed by 3812
Abstract
In recent years, polyphenols have been extensively studied due to their antioxidant, anticancer, and anti-inflammatory properties. It has been shown that anthocyanins, flavonols, and flavan-3-ols play an important role in the prevention of bacterial infections, as well as vascular or skin diseases. Particularly, [...] Read more.
In recent years, polyphenols have been extensively studied due to their antioxidant, anticancer, and anti-inflammatory properties. It has been shown that anthocyanins, flavonols, and flavan-3-ols play an important role in the prevention of bacterial infections, as well as vascular or skin diseases. Particularly, resveratrol, as a multi-potent agent, may prevent or mitigate the effects of oxidative stress. As the largest organ of the human body, skin is an extremely desirable target for the possible delivery of active substances. The transdermal route of administration of active compounds shows many advantages, including avoidance of gastrointestinal irritation and the first-pass effect. Moreover, it is non-invasive and can be self-administered. However, this delivery is limited, mainly due to the need to overpassing the stratum corneum, the possible decomposition of the substances in contact with the skin surface or in the deeper layers thereof. In addition, using resveratrol for topical and transdermal delivery faces the problems of its low solubility and poor stability. To overcome this, novel systems of delivery are being developed for the effective transport of resveratrol across the skin. Carriers in the micro and nano size were demonstrated to be more efficient for safe and faster topical and transdermal delivery of active substances. The present review aimed to discuss the role of resveratrol in the treatment of skin abnormalities with a special emphasis on technologies enhancing transdermal delivery of resveratrol. Full article
(This article belongs to the Special Issue Nanomedicine across Barriers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop